Short Interest in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Drops By 46.0%
Short Interest in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW) Drops By 46.0%
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 8,100 shares, a drop of 46.0% from the November 30th total of 15,000 shares. Based on an average daily volume of 15,600 shares, the days-to-cover ratio is presently 0.5 days.
科美拉生命科學控股有限公司（NASDAQ：CMRAW-獲取評級）是十二月份短期利益顯著下降的目標。截至 12 月 15 日，總共有 8,100 股短息，較十一月三十日共 15,000 股股份下降 46.0%。根據每日平均成交量 15,600 股，日數佔覆蓋率目前為 0.5 天。
Comera Life Sciences Price Performance
科美拉生命科學價格性能
CMRAW stock opened at $0.05 on Friday. The stock's 50 day moving average is $0.05. Comera Life Sciences has a 52 week low of $0.03 and a 52 week high of $0.70.
中國原材料股票上週五以 0.05 美元開盤。該股票的 50 日移動平均線為 0.05 美元。科美拉生命科學有一個 52 周低點 0.03 美元和 52 周高點 0.70 美元。
Institutional Trading of Comera Life Sciences
科美拉生命科學的機構交易
A hedge fund recently bought a new stake in Comera Life Sciences stock. Warberg Asset Management LLC bought a new stake in Comera Life Sciences Holdings, Inc. (NASDAQ:CMRAW – Get Rating) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 202,000 shares of the company's stock, valued at approximately $29,000.
對沖基金最近買入了科美拉生命科學股票的新股份。根據其最近向美國證券交易委員會（SEC）提交的文件，沃伯格資產管理有限責任公司在第二季度收購了科美拉生命科學控股有限公司（NASDAQ：CMRAW-獲得評級）的新股份。該基金買入了該公司股票的 202,000 股，價值約為 29,000 美元。
About Comera Life Sciences
關於科美拉生命科學
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
科美拉生命科學控股有限公司，是臨床前階段生命科學公司，開發了專有治療的內部產品組合，該產品結合了其專有配方平台 SQore。其 SQore 平台旨在實現靜脈注射（IV）生物製劑轉換為皮下（SQ）版本。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRAW)
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
- 獲取有關科美拉生命科學研究報告的免費副本
- 你應該熱身 Generac 股票的冬天嗎？
- 金塔拉治療學是一個隱藏的寶石嗎？
- 3 支長期持有的高收益股票
- 卡爾-緬因州發布創紀錄的季度，保持冷靜收入投資
- 特斯拉股票：公牛和熊出錯了什麼
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收科美拉生命科學日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關科美拉生命科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。